Phaseline

Targets › SLC2A1

SLC2A1 (Solute carrier family 2, facilitated glucose transporter member 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Hematology; next expected readout Jun 2027.

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. (UniProt, P11166)

Open in Phaseline: the race on SLC2A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Anna Raciborskafluorodeoxyglucose (18F-FDG)
Glucose analog positron emission tomography imaging agent
SLC2A1Phase 3HistiocytosisJun 2027

Conditions

Histiocytosis (1)

Modalities

small molecule (1)

Companies

Anna Raciborska (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.